Regentis Biomaterials (RGNT) on Wednesday filed a registration statement covering the potential resale of up to 3.81 million ordinary shares issued or issuable in connection with a June private placement.

The company said it will not receive proceeds from sales of the shares by the selling shareholders but may receive proceeds if the associated warrants are exercised for cash.

Shares of Regentis were up 1.6% in after-hours trading.